Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OLAPARIB Cause Chronic obstructive pulmonary disease? 10 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Chronic obstructive pulmonary disease have been filed in association with OLAPARIB (Lynparza). This represents 0.1% of all adverse event reports for OLAPARIB.

10
Reports of Chronic obstructive pulmonary disease with OLAPARIB
0.1%
of all OLAPARIB reports
1
Deaths
6
Hospitalizations

How Dangerous Is Chronic obstructive pulmonary disease From OLAPARIB?

Of the 10 reports, 1 (10.0%) resulted in death, 6 (60.0%) required hospitalization.

Is Chronic obstructive pulmonary disease Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OLAPARIB. However, 10 reports have been filed with the FAERS database.

What Other Side Effects Does OLAPARIB Cause?

Death (4,378) Malignant neoplasm progression (1,862) Nausea (1,582) Anaemia (1,455) Fatigue (1,437) Off label use (777) Vomiting (642) Drug ineffective (563) Diarrhoea (514) Asthenia (491)

What Other Drugs Cause Chronic obstructive pulmonary disease?

ALBUTEROL (2,916) TIOTROPIUM (2,895) BUDESONIDE\FORMOTEROL (2,279) FLUTICASONE\SALMETEROL (1,904) ADALIMUMAB (1,712) PREDNISONE (1,237) FLUTICASONE FUROATE\UMECLIDINIUM\VILANTEROL TRIFENATATE (1,145) MEPOLIZUMAB (1,107) FLUTICASONE FUROATE\VILANTEROL TRIFENATATE (967) DUPILUMAB (907)

Which OLAPARIB Alternatives Have Lower Chronic obstructive pulmonary disease Risk?

OLAPARIB vs OLARATUMAB OLAPARIB vs OLECLUMAB OLAPARIB vs OLIVE OIL\SOYBEAN OIL OLAPARIB vs OLMESARTAN OLAPARIB vs OLMESARTAN MEDOXOMIL

Related Pages

OLAPARIB Full Profile All Chronic obstructive pulmonary disease Reports All Drugs Causing Chronic obstructive pulmonary disease OLAPARIB Demographics